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Highlights 
x A topical decontamination regimen was introduced for haematology patients 
x Incidence of catheter-related bloodstream infections reduced significantly 
x Infection-free catheter survival times improved 
x Staphylococcus aureus infections were particularly reduced 
 
ABSTRACT 
Objectives. To assess impact of a topical decontamination regimen on rates of catheter-related 
bloodstream infections (CRBSI) in intensively-treated haematology patients. 
Methods. A historically-controlled cohort study was used to evaluate the effect of applying 
chlorhexidine or Octenisan® body washes and nasal Prontoderm® ointment for 5 days around the 
time of Hickman line insertion on the incidence of CRBSI and infection-free catheter time. Lines 
inserted during a 24 month period prior to implementation of the decolonisation regimen were 
compared with those inserted during a 12 month period after the intervention was applied. 
Results. During the post-intervention period, 163 lines were inserted in 147 patients, compared to 
303 lines in 242 patients in the pre-intervention period. CRBSI rates in treated and untreated 
patients respectively were 6.8 and 35.0 cases per 10,000 line-days by 21 days (p = 0.009), and 14.4 
and 26.0 cases respectively per 10,000 line-days by 180 days (p = 0.025).  
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The incidence rate of Staphylococcus aureus CRBSI in treated and untreated patients were 0.0 and 
4.6 cases per 10,000 line-days respectively (p = 0.012). Multivariable Cox regression estimated an 
81% probability (95% confidence interval 74% - 85%) that a treated line develops a CRBSI later than 
an untreated line by 21 days post-insertion.  
Conclusions. Implementation of this safe and effective topical decontamination regimen enhances 
routine CRBSI-prevention measures for haematology patients requiring central venous line insertion.  
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INTRODUCTION 
Catheter-related bloodstream infections (CRBSI) are a common and serious complication of central 
venous line placement. They cause significant morbidity and mortality where they occur, and place a 
significant financial burden on health services [1-3].  Patients treated intensively for haematological 
malignancies are particularly vulnerable to the adverse effects of CRBSI where they occur, but 
placement of a central venous access device is often unavoidable; being required for delivery of 
chemotherapy, immunotherapy, and supportive treatments such as fluids, antibiotics and blood 
products [4]. Infection is one of the commonest causes of death in this population and CRBSI 
contribute significantly to the numbers dying from infectious complications [5]. CRBSI are also the 
commonest reason for premature line removal, often at a time when patients are neutropenic and 
requiring the greatest degree of supportive care, hindering both successful treatment of the septic 
episode and delivery of other necessary therapies during the intensive phase of treatment [4,6].  
A number of different prevention strategies have been trialled with the aim of reducing 
CRBSI rates. Implementation of evidence-ďĂƐĞĚ  ?ďƵŶĚůĞƐ ? ŽĨ ĐĂƌĞ ŚĂǀĞ ďĞĐŽŵĞalmost universal. 
These variably specify infection control measures such as staff education and training; line insertion 
site; local antimicrobial dressing; daily review of central lines and removal of unnecessary lines. The 
composition of such care bundles varies between studies and their optimal composition remains a 
matter of debate. Even when well-established and consistently implemented, very few such 
packages of intervention reduce CRBSI rates to 0, leaving significant room for improvement [7,8]. 
Additional measures studied have included: use of antimicrobial-impregnated lines; antimicrobial 
line lock solutions; alcohol impregnated caps; antibacterial dressings and nasal mupirocin; however, 
data is lacking on the effectiveness of these measures in adult haematology patients, and associated 
adverse events have been reported [9-12].  
The addition of topical chlorhexidine or Octenisan® combined with nasal Prontoderm® to 
traditional CRBSI prevention measures has not previously been studied in intensively-treated 
haematology patients. Given the excellent safety profiles and reported efficacy of these agents in 
other populations, this combination is deserving of further study in this high risk patient group [13-
16]. 
In this study, we evaluate the efficacy of extended antimicrobial washes plus nasal 
Prontoderm®   ointment in addition to routine CRBSI-prevention measures around the time of 
central line insertion to reduce CRBSI rates and improve infection-free catheter times in 
haematology patients. 
 
 
MATERIALS AND METHODS 
Study Design 
This historically-controlled cohort study was designed to evaluate the impact of topical 
decolonisation therapy around the time of Hickman line insertion on the incidence of line infection 
and on infection-free catheter time in haematology patients. 
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Setting 
A large, tertiary care, adult haematology department in the UK, providing specialist haematology 
and stem cell transplantation services for a population of approximately 2 million. Hickman lines are 
routinely inserted for patients undergoing intensive chemotherapy treatment for acute leukaemia 
and those requiring autologous or allogeneic stem cell transplantation. 
 
Hickman Line Insertion and Care 
Hickman lines were placed or supervised by senior vascular radiologists in specialist angiographic 
laboratories. Under local anaesthesia, line insertion was preferentially into the right internal jugular 
vein under ultrasound guidance using Seldinger technique. Strict aseptic technique was followed, 
including: use of surgical chlorhexidine or betadine hand wash; sterile gown, gloves, surgical cap and 
face mask by operator; sterilisation of insertion site with 2% chlorhexidine solution and use of sterile 
drapes.  
Following insertion, line sites were dressed and inspected regularly.  No difference in line insertion 
technique, peri-procedural management or post-procedural ward care was implemented during the 
study period other than the defined intervention.  
 
Intervention 
A skin and nasal decontamination regimen was introduced by the hospital with the aim of reducing 
CRBSI rates, in October 2013.  This consisted of a 5 day course in total of decolonisation with daily 
topical chlorhexidine or Octenisan® (Schülke & Mayr UK Ltd) washes and three times per day 
bilateral nasal Prontoderm® (B. Braun Medical Ltd), administered by the patient themselves where 
possible or by staff members if required, with a patient information sheet provided to facilitate this.  
The course began 2 days before planned line insertion date, continued through the day of insertion 
and for 2 days afterwards therefore was a total of 5 days with 2 of these being prior to the date of 
line insertion.  
 
Patients 
Haematology patients having Hickman lines inserted were identified through the Radiology 
department database. Patients included in the  pre-intervention group had Hickman lines inserted 
during a 24 month period from 1/1/11. 
To allow a run-in period for staff to become familiar with the regimen, patients included in 
the post-intervention group had lines inserted during a 12 month period from 1/4/14. Lines inserted 
in other hospitals or outside the Radiology department were not included in the study. 
Dates of line removal were ascertained from ƚŚĞƚƌƵƐƚ ?ƐĐŽĚŝŶŐĚĂƚĂďĂƐĞ ? through receipt of 
a line tip by the Microbiology department; or by review of patient notes, allowing duration of line 
presence to be calculated. All lines were followed up until removal or 180 days post insertion, 
whichever came sooner. 
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Laboratory Methods 
Culture of all line lumens along with peripheral blood was routinely performed in response to the 
development of fever in patients with a Hickman line. Blood was incubated in the Microbiology 
laboratory using the Bactec FX® continuously monitored blood culture system (Becton-Dickinson and 
co). Time to positivity was recorded within the Laboratory Information Management System via a 
direct interface. Following subculture from positive bottles, organisms were speciated using the 
MALDI Biotyper® (Bruker) and susceptibility testing performed in line with BSAC/EUCAST guidelines 
using a multipoint breakpoint agar or disc method [17].  
Tips of lines removed due to suspected infection were sent for culture, performed by semi-
quantitative roll plate method in line with the UK Standards for Microbiology Investigations [18]. 
Identification and susceptibility testing of cultured organisms was as detailed above. 
 
Definitions 
Line infections were classed as definite if 1 of the following 3 criteria were fulfilled: indistinguishable 
organism in peripheral and line culture with line culture positive ш2 hours earlier than peripheral; 
indistinguishable organism in 2 simultaneous line cultures with one culture positive ш2 hours earlier 
than the other if peripheral blood culture not sent; organism grown in line or peripheral blood 
culture indistinguishable from organism cultured from line tip post-withdrawal. Definitions adapted 
from Centers for Disease Control and Prevention definition [19]. 
 Line infections were classed as probable if fulfilling 1 of the following 3 criteria: 
indistinguishable organism in peripheral and line culture with < 2hours differential time to positivity 
and line removed within 7 days due to clinical suspicion of line infection with otherwise unexplained 
pyrexia; culture of indistinguishable organism from both lines with negative peripheral culture and 
otherwise unexplained pyrexia; repeated positive cultures from same line lumen >24 hours apart 
with indistinguishable organism and otherwise unexplained pyrexia. 
Organisms were classed as indistinguishable if of the same species and ч1 different antibiotic 
susceptibilities using standard panel of agents. 
 
Outcomes 
Main endpoints were CRBSI-free catheter time and overall incidence rate of early-onset CRBSI, 
occurring up to 21 days post line insertion. To evaluate longer-term effects of the intervention, we 
also assessed episodes of CRBSI up to 180 days of line insertion. Staff compliance with the protocol 
was determined by prescription of decolonisation therapy. Patient adherence to therapy was not 
assessed. 
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Statistical Methods 
Per-protocol analysis was carried out to determine the impact of decolonisation therapy on the 
incidence of CRBSI and infection-free line survival time. Incidence rates of CRBSI were calculated as 
number of new infections per 10,000 line-days and compared between treatment arms by 
calculating incidence rate ratios with exact 95% confidence intervals (95% CI) and Mid-P tests. Time 
at risk for CRBSI (infection-free survival time) was calculated as number of days between line 
insertion and line removal for episodes without CRBSI and as interval between line insertion and 
onset of first infection for episodes with CRBSI. Kaplan ?Meier estimates of infection-free survival 
were obtained and survival curves were compared between treatment groups using log-rank test. 
Differences in baseline covariates were assessed using chi-ƐƋƵĂƌĞ Žƌ &ŝƐŚĞƌ ?Ɛ ĞǆĂĐƚ ƚĞƐƚ ĨŽƌ
categorical variables and Mann-Whitney U-test for continuous variables. Multivariable Cox 
proportional hazards regression was used to obtain adjusted hazard ratios (HR) and 95% CIs 
correcting for differences in baseline covariates. The probability that a line in the decolonisation 
therapy group develops a CRBSI later than an untreated line insertion was estimated as P = 1 - HR/(1 
+ HR) [20]. 
Lines removed earlier than 21 days of insertion were considered censored observations in 
the survival analysis of early-onset CRBSI. Study end was defined at 180 days post line insertion. 
Cluster-robust standard error estimation was used in Cox regression to account for potential 
dependencies between different line-insertion episodes in the same patient. Statistical significance 
ǁĂƐĚĞĨŝŶĞĚĂƚƉч ? ? ? ? ? 
Various sensitivity analyses were performed to assess the likely effects of decolonisation 
therapy under different conditions. As decolonisation therapy was not prescribed in 19 (11.7%) of 
the inserted lines during the post-intervention period, an intention-to-treat analysis was carried out  
comparing CRBSI rates and infection-free times between assignment arms (pre-intervention vs. post-
intervention). The data were also analysed on a modified intention-to-treat basis excluding the 19 
lines that did not receive treatment during the post-intervention period. Finally, all analyses were 
repeated by excluding probable infections.  
 
RESULTS 
Baseline Data 
During the pre-intervention period, 303 lines were inserted in 242 patients for a total of 24,212 line-
days. In the post-intervention period, 163 lines were inserted in 147 patients with a total of 13,648 
line-days. Decolonisation therapy was prescribed for 144 (88.3%) of the 163 inserted lines in the 
post-intervention period resulting in a total of 12,348 line-days among treated patients and 25,512 
line-days among untreated patients. Decolonisation therapy was chlorhexidine and Prontoderm® in 
133 cases and Octenisan® and Prontoderm®
 
in 11 cases. 
Treatment arms were similar with respect to patient age, sex, receipt of total parenteral 
nutrition and history of diabetes. Treatment arms differed significantly in primary diagnosis, with 
patients who were prescribed therapy being more likely to have received stem cell transplants 
(Table 1).  
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Incidence of CRBSI 
A total of 2 early-onset CRBSIs were detected up to day 21 post-insertion in patients who received 
decolonisation therapy, compared with 22 in untreated line insertions. The rate of early-onset CRBSI 
was 81% lower among the treated line-insertions than among those untreated (6.8 vs 35.0 cases per 
10,000 lines-days at risk, p = 0.009).   
Overall, 17 CRBSI were identified within 180 days following line-insertion in the 
decolonisation therapy group, as compared with 62 in the untreated group. The rate of CRBSI was 
45% lower among the treated line-insertion episodes than among those untreated (14.4 vs. 26.0 
cases per 10,000 lines-days at risk, p = 0.025).  
If probable infections were excluded from analyses, relative rate reductions were 82% (p = 
0.056) for definite early-onset infections and 58% (p = 0.016) for definite any-onset infections, 
respectively (Table 2). 
Among the 24 early-onset CRBSI detected in this study, the most common pathogens were 
coagulase-negative Staphylococcus (29.2%), Staphylococcus aureus (29.2%) and Enterobacteriaceae 
(20.8%). Among the 79 any-onset CRBSI, most common aetiologic agents included coagulase-
negative Staphylococcus (30.4%), Enterobacteriaceae (22.8%), non-fermenting Gram-negative 
bacteria (16.5%), and Staphylococcus aureus (13.9%). Following decolonisation therapy, a trend to 
reduced CRBSI incidence was observed for each bacterial pathogen except for Corynebacterium and 
non-fermenting Gram-negative bacteria (Table 3). The reduction was statistically significant in the 
case of Staphylococcus aureus, where early-onset infections reduced from 11.1 to 0.0 cases per 
10,000 lines-days at risk (p = 0.069) and any-onset infections reduced from 4.6 to 0.0 cases per 
10,000 lines-days at risk (p = 0.012). 
 
CRBSI-Free Survival Times 
The Kaplan-Meier estimates of 21 day infection-free rate after line insertion were 98.6% for the 
decolonisation therapy group and 92.8% for the untreated group. At 180 days following line 
insertion, estimated infection-free rate was 76.0% in the treated group and 66.5% in the untreated 
group (Figure 1). The log-rank test revealed a statistically significant difference between infection-
free rates over time (p = 0.028). 
Further investigation with a Cox proportional hazards analysis (Table 4), controlling for 
patient age, sex, primary diagnosis, type of transplant and history of diabetes, indicated that, at any 
given time, line-insertions that had been prescribed decolonisation therapy were significantly less 
likely to develop an early-onset CRBSI compared to those in the untreated group (adjusted HR = 
0.24; 95% CI 0.17  ? 0.35). This corresponds to an 81% probability (95% CI 74% - 85%) that a treated 
line develops an early-onset CRBSI later than an untreated line.  
Extending follow-up time to 180 days of line insertion, our analysis showed a reduced risk of 
CRBSI in the decolonisation therapy group (adjusted HR = 0.61; 95% CI 0.46  ? 0.79), with an 
estimated 62% chance (95% CI 56% - 68%) of treated lines developing a CRBSI later than untreated 
lines.  
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Sensitivity Analyses 
Table 5 presents the results of multivariable Cox regression for the risk of CRBSI under different 
conditions. Exclusion of probable infections did not alter the results in per-protocol analysis. Results 
were also similar when line insertions that were not prescribed decolonisation therapy during the 
post-intervention period (n = 19) were excluded from analysis. 
An intention-to-treat analysis produced less pronounced and not statistically significant 
relative hazard reductions both for early-onset CRBSI (adjusted HR = 0.58; p = 0.199) and any-onset 
CRBSI (adjusted HR = 0.91; p = 0.477). The incidence rate of early-onset CRBSI during the post-
intervention period was lower than the pre-intervention period (15.1 vs 32.1 cases per 10,000 lines-
days at risk, respectively) but the difference was not statistically significant (p = 0.127). At 180 days 
post line-insertion, incidence rates of CRBSI were similar between the pre- and post- intervention 
periods (23.2 vs 20.2 cases per 10,000 lines-days at risk, respectively; p = 0.566).  
 
DISCUSSION 
We report a significant reduction in CRBSI rates and improved infection-free line survival times with 
the use of a dual skin and nasal decontamination regimen using chlorhexidine or Octenisan® washes 
and Prontoderm® nasal ointment, in a population of intensively-treated haematology patients with 
Hickman catheters.  
Multiple factors contribute to the high rate of CRBSI in haematology patients and to the 
frequency of associated complications and mortality. These include prolonged neutropenia, 
immunosuppression and mucosal barrier breakdown, secondary to an often synergistic interaction 
between the underlying conditions themselves and the intensive cytotoxic therapy administered to 
treat them [3]. Central lines are also often in situ for longer periods in cancer patients compared to 
many others, another factor demonstrated to increase CRBSI risk [2,21].  
Haematology patients are often treated intensively with curative intent or with the aim of 
inducing long-lasting remission with good quality of life. They therefore have much to gain from 
successful treatment but much to lose where infectious complications intervene to complicate and 
delay treatment. CRBSIs caused by drug-resistant organisms are frequent and present a particular 
challenge [22]. Given the difficulties in effectively treating such infections, and the high morbidity 
and mortality burden associated with them, prevention of CRBSIs is a particularly important goal in 
this patient population [3].  
A reduction in CRBSI rates, such as that reported in our study, would be expected to 
translate into a clinically relevant reduction in serious complications including overwhelming sepsis 
and early line removal. The longer infection-free line survival times after decolonisation therapy will 
also facilitate delivery of necessary treatment and supportive therapy.  
Reduction in early infection rate was particularly pronounced in this study, at a time when 
extraluminal route of infection predominates and measures to reduce contamination around the 
time of CVC insertion are therefore unsurprisingly most likely to improve infection rates [2,23]. The 
spectrum of causative organisms in our patient group was similar to that reported in previous 
studies of CRBSI in haematology and oncology patients, with the majority of cultured organisms 
being coagulase negative staphylococci, Staphylococcus aureus,  Enterobacteriaceae, and other gram 
negative organisms [6,24,25]. Of all causative pathogens, reduction in Staphylococcus aureus CRBSI 
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was most significant following implementation of our dual decolonisation regime, an organism 
commonly reported as a cause of early CRBSI  [6,24,25].  
Reduction in infection rates was not statistically significant when analysed on an intention-
to-treat basis, indicating that a programme to ensure good compliance must be introduced along 
with the policy of peri-procedural decolonisation. Compliance was assessed by review of drug charts 
to determine whether decolonisation therapy had been prescribed as per protocol. As most of the 
decolonisation therapy was self ?administered and not necessarily in hospital, no further data on 
compliance is available beyond information on decolonisation prescription. Given that 100% 
compliance with the prescribed decontamination regimen is unlikely, and true compliance therefore 
likely to be less than that assumed by the analysis above, the magnitude of reported reduction in 
infection rate and improvement in infection-free line survival could be expected to be even greater 
than those reported here if 100% compliance were assured.  
A higher proportion of patients underwent stem cell transplantation in the treatment group 
than the pre-intervention group.  We hypothesise that this is due to the involvement of highly 
trained transplant nurse specialists overseeing care for this particular patient group and ensuring 
strict adherence to prescribing policies, as well as to a general increase in transplant activity within 
the department over the course of the study. 
We recommend routine implementation of a peri-procedural decontamination regimen 
using chlorhexidine or Octenisan® body washes and nasal Prontoderm® application to reduce CRBSI 
rates and improve infection-free line survival in intensively treated haematology and stem cell 
transplant patients. This is in addition to the traditional bundle of infection-prevention measures 
including aseptic technique at time of line insertion, staff training and education, and rigorous 
adherence to hand washing policies. Given the importance of compliance in attaining the reported 
reduction in infection rate, meticulous attention to ensuring staff and patient adherence to 
decolonisation therapy is vital.  
We suggest that a programme of staff education along with the provision of verbal and 
written patient information on the rationale for such a regimen will aid compliance, and that 
specialist haematology nurses are well placed to oversee the introduction and ongoing 
implementation of these measures. Audit of CRBSI rates in individual units before and after 
implementation of a peri-procedural decontamination regimen is recommended, as well as 
monitoring of compliance with prescription and administration policy. While compliance with 
prescription policy is relatively easily assessed, compliance with administration will necessarily be 
more challenging to measure. Asking patients to sign a pre-printed calendar with the dates and 
times of administration may be one method, albeit imperfect, by which an estimation of compliance 
with administration may be gained.  
This particular dual decolonisation therapy regimen now has proven efficacy in both the 
critical care and haematology settings. Further research is necessary to determine whether these 
results can be extrapolated to other populations such as patients undergoing renal replacement 
therapy and those being treated for solid tumours. No cost-effectiveness analysis has been carried 
out in this study and is also an area requiring further investigation.   
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Figure 1 Kaplan-Meier estimates of the probability of CRBSI-free survival 
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Table 1. Comparison of baseline characteristics of Hickman line-insertion episodes per treatment 
arm 
 Treatment arm 
Characteristic 
Untreated lines 
(n = 322) 
Treated lines  
(n = 144) P Value 
Line-days, median (total)    
Overall 59.0 (25512) 63.5 (12348) 0.176 
At risk
a
 51.5 (23871) 59.0 (11821) 0.081 
Patient age, median (IQR) 57 (45 - 65) 56 (47 - 65) 0.992 
Female sex, n (%) 103 (32.1) 56 (38.9) 0.153 
Primary diagnosis, n (%)   0.042 
Myeloma 95 (29.5) 46 (31.9)  
Lymphoma 91 (28.3) 30 (20.8)  
Acute myelogenous leukaemia 59 (18.3) 23 (16.0)  
Acute lymphoid leukaemia 39 (12.1) 14 (9.7)  
Chronic myelogenous leukaemia  7 (2.2) 10 (6.9)  
Other
b
 31 (9.6) 21 (14.6)  
Total parenteral nutrition, n (%) 12 (3.7) 2 (1.4) 0.244 
Diabetes, n (%) 17 (5.3) 11 (7.6) 0.322 
Type of transplant, n (%)   <0.001 
None 152 (47.2) 39 (27.1)  
Autologous 108 (33.5) 57 (39.6)  
Allogeneic 62 (19.3) 48 (33.3)  
a
 Line-days before onset of infection. 
b
 Includes aplastic anaemia (n=15), chronic lymphocytic leukaemia (n=10), myelodysplastic 
syndromes (n=12), myelofibrosis (n=5), and non-haematological diagnosis (n=10). 
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Table 2. Incidence rates of CRBSI and median times to infection according to treatment arm 
 Treatment arm 
Incidence Rate 
Ratio (95% CI) P Value Type of infection 
Untreated 
lines 
(n = 322) 
Treated 
lines 
(n = 144) 
Early onset CRBSI
a
     
No. of infections 22 2   
Median time to infection 
(days) 
13.5 11.0   
Line-days at risk
b
 6294 2936   
Incidence rate
c
 35.0 6.8 0.19 (0.02 - 0.79) 0.009 
Early-onset definite CRBSI
a
     
No. of infections 12 1   
Median time to infection 
(days) 
13.5 14.0   
Line-days at risk
b
 6348 2949   
Incidence rate
c
 18.9 3.4 0.18 (0.00 - 1.21) 0.056 
Any-onset CRBSI
d
     
No. of infections 62 17   
Median time to infection 
(days) 
37.5 62.0   
Line-days at risk
e
 23871 11821   
Incidence rate
c
 26.0 14.4 0.55 (0.30 - 0.96) 0.025 
Any-onset definite CRBSI
d
     
No. of infections 39 8   
Median time to infection 
(days) 
45.0 76.5   
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Line-days at risk
e
 24765 12175   
Incidence rate
c
 15.7 6.6 0.42 (0.17 - 0.91) 0.016 
Abbreviations: CRBSI, catheter-related bloodstream infection; CI, confidence interval. 
a 
Includes infections that occurred within 21 days of line insertion. 
b
 Duration of lines was calculated until onset of infection for infected patients and up to line-removal 
or 21 days post insertion for uninfected patients. 
c 
Number of infections per 10,000 line-days at risk. 
d
 Includes infections occurring up to 180 days post line insertion. 
e
 Duration of lines was calculated until onset of infection for infected patients and up to line-removal 
or 180 days post insertion for uninfected patients.  
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Table 3. Incidence of CRBSI by type of aetiologic organism 
 
Untreated lines  
(n = 322) 
Treated lines  
(n = 144)  
Infecting organism 
No. of 
infections 
Incidence 
Rate
a
 
No. of 
infections 
Incidence 
Rate
a
 P value 
Coagulase negative 
staphylococcus 
     
Early onset CRBSI
b
 6 9.5 1 3.4 0.361 
All CRBSI
c
 17 7.1 7 5.9 0.703 
Staphylococcus aureus      
Early onset CRBSI
b
 7 11.1 0 0.0 0.069 
All CRBSI
c
 11 4.6 0 0.0 0.012 
Alpha Haemolytic streptococcus      
Early onset CRBSI
b
 1 1.6 0 0.0 0.682 
All CRBSI
c
 3 1.3 1 0.8 0.797 
Enterococcus      
Early onset CRBSI
b
 1 1.6 0 0.0 0.682 
All CRBSI
c
 1 0.4 0 0.0 0.669 
Corynebacterium      
Early onset CRBSI
b
 1 1.6 1 3.4 0.636 
All CRBSI
c
 3 1.3 1 0.8 0.797 
Enterobacteriaceae      
Early onset CRBSI
b
 5 7.9 0 0.0 0.147 
All CRBSI
c
 15 6.3 3 2.5 0.139 
Non-fermenting Gram negative      
Early onset CRBSI
b
 0 0.0 0 0.0 1.000 
All CRBSI
c
 9 3.8 4 3.4 0.887 
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Anaerobe      
Early onset CRBSI
b
 1 1.6 0 0.0 0.682 
All CRBSI
c
 2 0.8 0 0.0 0.447 
Mycobacterium chelonae      
Early onset CRBSI
b
 0 0.0 0 0.0 1.000 
All CRBSI
c
 1 0.8 1 0.4 0.662 
Total      
Early onset CRBSI
b
 22 35.0 2 6.8 0.009 
All CRBSI
c
 62 26.0 17 14.4 0.025 
 
Abbreviations: CRBSI, catheter-related bloodstream infection. 
a 
Number of infections per 10,000 line-days at risk 
b
 Includes infections that occurred within 21 days of line insertion. 
c
 Includes infections occurring up to 180 days post line insertion. 
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Table 4. Results of multivariable Cox proportional hazards regression analysis for the risk 
of catheter-related bloodstream infection   
 Early-onset CRBSI
a
 Any-onset CRBSI
b
 
Variable 
Adjusted 
HR 95% CI P value 
Adjusted 
HR 95% CI P value 
Decolonisation therapy       
Untreated 1.00 - - 1.00 - - 
Treated 0.24 0.17 - 
0.35 
<0.001 0.61 0.46 - 
0.79 
<0.001 
Male sex 1.65 0.84  ? 
3.26 
0.147 0.95 0.73  ? 
1.23 
0.700 
Age 1.00 0.98  ? 
1.01 
0.518 0.99 0.98  ? 
1.00 
0.194 
Primary diagnosis       
Myeloma 0.73 0.23  ? 
2.37 
 
1.07 
0.63  ? 
1.80 
0.812 
Lymphoma 0.30 0.10  ? 
0.87 
 
1.00 
0.69  ? 
1.47 
0.986 
Acute myelogenous 
leukaemia 
0.85 0.39  ? 
1.85 
 
1.37 
0.91  ? 
2.07 
0.127 
Acute lymphoid 
leukaemia 
0.86 0.32  ? 
2.31 
 
1.05 
0.67  ? 
1.64 
0.839 
Other
c
 1.00 - - 1.00 - - 
Diabetes 3.27 1.16  ? 
9.20 
0.025 1.43 0.72 - 
2.87 
0.306 
Type of transplant       
None 1.00 - - 1.00 - - 
Autologous 0.23 0.10 - 
0.54 
0.001 
0.37 
0.26  ? 
0.52 
<0.001 
Allogeneic 0.30 0.11 - 
0.85 
0.024 
0.55 
0.38  ? 
0.79 
0.001 
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Abbreviations:  CRBSI,  catheter-related bloodstream infection; HR, hazard ratio; 
CI, confidence interval. 
a 
Includes infections occurring up to 21 days post line insertion. 
b
 Includes infections that occurred within 180 days of line insertion. 
c
 Includes aplastic anaemia, CLL, chronic myelogenous leukaemia, myelodysplastic 
syndromes, myelofibrosis, and non-haematological diagnoses. 
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Table 5. Results of multivariable Cox proportional hazards regression for the risk of 
catheter-related bloodstream infection under different conditions (sensitivity analyses)   
 
Per-protocol analysis
a
 Intention-to-treat 
analysis
b
 
Modified intention-to-
treat analysis
c
 
Type of 
infection 
aHR
d
 95% CI P 
value 
aHR
d
 95% CI P 
value 
aHR
d
 95% CI P 
value 
Early-onset 
CRBSI, all
e
 
0.24 0.17 - 
0.35 
<0.001 0.58 0.25  ? 
1.34 
0.199 0.26 0.18  ? 0.40 <0.001 
Early-onset 
CRBSI, 
definite
e
 
0.26 0.14  ? 
0.48 
<0.001 0.69 0.20  ? 
2.31 
0.541 0.26 0.10  ? 0.69 0.008 
Any-onset 
CRBSI, all
f
 
0.61 0.46 - 
0.79 
<0.001 0.91 0.71  ? 
1.18 
0.477 0.68 0.55  ? 0.83 <0.001 
Any-onset 
CRBSI, 
definite
f
 
0.46 0.30  ? 
0.69 
<0.001 0.86 0.58  ? 
1.27 
0.454 0.52 0.39  ? 0.71 <0.001 
 
Abbreviations:  aHR, adjusted Hazard Ratio; CI, confidence interval, CRBSI, catheter-related 
bloodstream infection. 
a
 Compares line-insertion episodes that were prescribed decolonisation therapy (n = 144) to 
those that did not (n = 322). 
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b
 Compares line-insertion episodes in the post-intervention period (n = 163) to those in the pre-
intervention period (n = 303). 
c
 Compares line-insertion episodes in the post-intervention period (n = 144) to those in the pre-
intervention period (n= 303), excluding line insertion that were not prescribed decolonisation 
therapy during the post-intervention period (n = 19). 
d
 Controlling for the effects of patient age, sex, primary diagnosis, type of transplant, and 
history of diabetes. 
e
 Includes infections that occurred within 21 days of line insertion. 
f
 Includes infections occurring up to 180 days post line insertion. 
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